IDEXX Laboratories (NASDAQ: IDXX) — Perfil da empresa, notícias e dados financeiros
IDEXX Laboratories specializes in veterinary diagnostics and software, striving to enhance health outcomes for animals worldwide.
IDEXX Laboratories
IDEXX Laboratories is a biotechnology and diagnostic company that develops, manufactures, and distributes products and services for veterinary, livestock, poultry, dairy, and water testing applications. The company operates primarily through its Companion Animal Group, offering in-clinic point-of-care diagnostic analyzers, rapid assay SNAP tests, reference laboratory diagnostic and pathology services, and cloud-based practice management software. Additionally, it provides diagnostic tests for livestock health and disease monitoring, milk quality assurance, and water microbiology testing solutions to identify bacterial contamination. Headquartered in Westbrook, Maine, the company serves veterinary practices, agricultural producers, and water utilities across more than 175 countries worldwide.
Resumo
Operações
Produtos e/ou serviços de IDEXX Laboratories
- Reference Laboratory Services: Global network of reference laboratories providing comprehensive diagnostic testing, digital cytology, pathology services, and specialized diagnostic profiles for veterinary practices, supported by medical consulting specialists and automated sample processing systems.
- Point-of-Care Diagnostic Analyzers: In-clinic diagnostic instruments including chemistry, hematology, urinalysis, and cellular analyzers that deliver real-time reference laboratory-grade blood and bodily fluid testing results directly at veterinary practices to guide immediate clinical decisions.
- Practice Management Software: Cloud-based and on-premise veterinary practice management platforms, clinical workflow software, and client communication applications that automate appointment scheduling, medical billing, diagnostic integration, and electronic health record maintenance for animal hospitals.
- Rapid Assay Diagnostic Tests: Portable single-use testing kits utilizing enzyme-linked immunosorbent assay technology to rapidly screen companion animals for infectious diseases, vector-borne pathogens like heartworm and Lyme disease, and specific hormonal or inflammatory biomarker levels.
- Water Quality Diagnostic Products: Microbiological testing supplies, media reagents, and automated detection systems used by municipal utilities, commercial laboratories, and industrial facilities to monitor drinking water, wastewater, and recreational water for bacterial contaminants.
- Livestock and Poultry Diagnostics: Diagnostic test kits, enzyme immunoassay reagents, and polymerase chain reaction assays used by agricultural producers, veterinarians, and commercial testing laboratories to screen cattle, swine, poultry, and sheep for infectious diseases and pregnancy status.
equipe executiva do IDEXX Laboratories
- Jonathan J. MazelskyExecutive Chairman
- Andrew EmersonExecutive VP, CFO & Treasurer
- Michael J. LaneExecutive VP and GM Global Reference Laboratories, Diagnostic Solutions & Information Technology
- Martin SmithExecutive Vice President of Global Operations and R&D
- Michael G. EricksonCEO, President & Director
- Bob AsmannSenior Vice President of Global Operations
- Amit GuptaSenior VP, Chief Digital & Information Officer
- Sharon E. UnderbergExecutive VP, General Counsel, & Corporate Secretary
- Julie GodonSenior VP & Global Marketing Officer
- Michael P. JohnsonExecutive VP & Chief Human Resources Officer
Últimas notícias sobre a IDEXX Laboratories
IDEXX expands Faecal Dx testing in UK
United StatesIDEXX acquires CoVetAI veterinary AI
United StatesIDEXX revenue rises 10% to $1.22 billion
United StatesIDEXX raises outlook as high pet healthcare demand drives revenue surge
United StatesIDEXX expands canine cancer detection to UK with IDEXX Cancer Dx™ Panel launch
United StatesIDEXX profit jumps 18% as diagnostics demand defies sector headwinds
United States
Principais indicadores financeiros
Resultados divulgados pela IDEXX Laboratories, em USD.
- Cap. de mercado
- 44,3 bi
- Receita (TTM)
- 4,6 bi
- P/L
- 39.6
- LPA (diluído, TTM)
- 14.2
- Dividend yield
- —
- Margem de lucro
- 25.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 4,3 bi | 1,4 bi | 1,1 bi | |
| 3,9 bi | 1,1 bi | 887,9 mi | |
| 3,7 bi | 1,1 bi | 845 mi | |
| 3,4 bi | 898,8 mi | 679,1 mi |